Psychologists in Wallingford, VT Accepting Medicare
5 Psychologists found. Showing 1 - 5
 Dr. Michael William Kesler, PH.D. Psychologist - Counseling Medicare: Not Enrolled in Medicare Practice Location: 167 N Main St, Wallingford, VT 05773 Phone: 802-446-3577 Fax: 802-446-3801 |
Dr. Dean Jm Mooney, PH.D. Psychologist - Clinical Medicare: May Accept Medicare Assignments Practice Location: 167 North Main St., Wallingford, VT 05773 Phone: 802-446-3577 Fax: 802-446-3801 |
 Mrs. Henna K Chandel, BS Psychologist Medicare: Not Enrolled in Medicare Practice Location: 167 N Main St, Wallingford, VT 05773 Phone: 802-446-3577 |
Lindsey Gail Johnston, M.S. Psychologist - Clinical Medicare: Not Enrolled in Medicare Practice Location: 167 N Main St, Wallingford, VT 05773 Phone: 802-446-3577 Fax: 802-446-3801 |
Mr. Seth Joshua Peets, M.A., CAGS Psychologist - School Medicare: Not Enrolled in Medicare Practice Location: 167 N Main St, Wallingford, VT 05773 Phone: 802-446-3577 |
News Archive
Perisylvian polymicrogyria gene found
Researchers have identified the genetic basis for bilateral perisylvian polymicrogyria, the most common form of regional polymicrogyria.
Overall time spent on social media does not increase anxiety or depression in teenagers
The amount of time teenagers spend on social networking sites has risen 62.5 percent since 2012 and continues to grow. Just last year, the average time teenagers spent on social media was estimated as 2.6 hours per day. Critics have claimed that more screen time is increasing depression and anxiety in teenagers.
Advancements in total hip replacement procedure make young patients opt for surgery
Traditionally, total hip replacement surgery was performed on the elderly, but these days, advancements in the procedure have patients opting for the surgery much earlier in life.
FDA grants orphan drug designation to pralatrexate for treatment of advanced TCC of urinary bladder
Allos Therapeutics, Inc. announced today that the U.S. Food and Drug Administration has granted orphan drug designation to pralatrexate for the treatment of advanced or metastatic transitional cell carcinoma of the urinary bladder, a form of bladder cancer. The Company is currently investigating pralatrexate in a Phase 2 clinical study in patients with advanced or metastatic relapsed TCC of the urinary bladder.
› Verified 2 days ago